Skip to main content
. 2013 Oct 1;2(4):241–248. doi: 10.12860/JNP.2013.38

Table 1 . Baseline characteristics of all patients are given in Table 1 .

Treatment Scr
(mg/dl) 		U/Pro
(g/d) 		sPLA2
(Pg/ml) 		aPLA2-R diag/dur
(months) 		Age/sex Pts
Cyclo/P/ACE/ARB 1.6 800 nd Neg iMN/63 55/M 1
Cyclo/P/ACE/ARB 1.2 700 nd Neg iMN/71 48/M 2
Cyclo/P/ACE/ARB/MMF 1.3 2700 248 Neg iMN/37 35/F 3
Cyclo/P/ACE/ARB 1.7 1100 nd Neg iMN/23 41/M 4
Cyclo/P/ACE/ARB 2.2 3000 31 Neg iMN/16 38/F 5
Cyclo/P/ACE/ARB 1.2 3200 nd Neg iMN/11 27/F 6
Cyclo/P/ACE/ARB/MMF 9.5 800 nd 1/10 iMN/67 52/F 7. Ƕ
Cyclo/P/ACE/ARB 1.4 3600 2200 1/100 iMN/15 38/M 8
Cyclo/P/ACE/ARB 1.0 4300 nd 1/200 iMN /10 25/M 9
Cyclo/P/ACE/ARB 2.0 1900 nd 1/10 iMN/8 32/F 10.
Cyclo/P/ACE/ARB 1.2 900 nd 1/10 iMN/ 15 25/F 11.
Cyclo/P/ACE/ARB 1.3 1200 nd 1/10 iMN/ 14 27/F 12.
Cyclo/P/ACE/ARB 2.0 3900 nd 1/10 iMN / 7 30/F 13.
Cyclo/P/ MMF/ACE 2.0 770 nd 1/10 iMN/ 8 28/M 14. Ţ
Cyclo/P/ACE/ARB 2.0 4900 2524 1/800 iMN /11 31/M 15.
Cyclo/P/ACE/ARB 2.0 1770 2660 1/400 iMN /16 25/F 16.
Cyclo/P/ACE/ARB 1.6 2400 nd 1/200 iMN/ 12 34/M 17.
Cyclo/P/ACE/ARB 1.7 2200 2000 1/200 iMN/ 9 28/M 18.
Cyclo/P/ACE/ARB 1.0 900 nd 1/10 - iMN/ 10 18/M 19.
Cyclo/P/ACE/ARB 2.2 3800 1100 1/10 iMN/ 56 50/F 20.
Cyclo/P/ACE/ARB 1.5 3100 7700 1/800 iMN/17 29/M 21.
Cyclo/P/ACE/ARB 1.2 2700 10863 1/1000 iMN/12 33/M 22.
Cyclo/P/ACE/ARB 1.4 4300 4381 1/800 iMN/20 30/F 23.
Cyclo/P/ACE/ARB 1.7 2100 nd Neg SLE(MN)/23 26/F 24.
ACE/ARB 2.1 2800 nd Neg HBV(MN)/ 14 28/M 25.
Cyclo/P/ACE/ARB 1.1 4100 nd Neg FSGS/16 22/M 26.
Cyclo/P/ACE/ARB 1.3 1100 nd Neg FSGS/45 18/M 27.
Cyclo/P/ACE/ARB 3.1 3500 nd Neg FSGS/38 21/F 28.
Cyclo/P/ACE/ARB 1.8 5500 nd Neg MCD/24 24/M 29.
Cyclo/P/ACE/ARB 1.1 2800 nd Neg MPGN/30 23/M 30.
HHS Vulnerability Disclosure